CAJ | 학술논문

目的系统比较吉西他滨联合铂类与吉西他滨单药治疗晚期胰腺癌的临床疗效。方法检索PubMed、Embase、Cochrane Library、CNKI和万方数据库查找相关文献。主要观察终点为总生存时间（ OS），次要观察终点为无疾病进展生存期（PFS），客观缓解率（ORR）。结果10篇临床试验纳入Meta分析。共纳入2711例患者，其中吉西他滨联合铂类组1401例，吉西他滨单一治疗组1310例。吉西他滨联合治疗组较吉西他滨单一治疗组没有显著提高晚期胰腺癌患者的OS[HR＝1.00，95%CI（0.98-1.01），P ＝0.610]与PFS[HR＝1.00，95%CI（0.98-1.01），P ＝0.704]。但吉西他滨联合治疗组显著改善晚期胰腺癌患者的ORR[RR＝1.52，95%CI（1.27-1.82），P ﹤0.001]。结论吉西他滨联合铂类药物显著改善晚期胰腺癌患者ORR，但并没有显著改善OS与PFS。
목적계통비교길서타빈연합박류여길서타빈단약치료만기이선암적림상료효。방법검색PubMed、Embase、Cochrane Library、CNKI화만방수거고사조상관문헌。주요관찰종점위총생존시간（ OS），차요관찰종점위무질병진전생존기（PFS），객관완해솔（ORR）。결과10편림상시험납입Meta분석。공납입2711례환자，기중길서타빈연합박류조1401례，길서타빈단일치료조1310례。길서타빈연합치료조교길서타빈단일치료조몰유현저제고만기이선암환자적OS[HR＝1.00，95%CI（0.98-1.01），P ＝0.610]여PFS[HR＝1.00，95%CI（0.98-1.01），P ＝0.704]。단길서타빈연합치료조현저개선만기이선암환자적ORR[RR＝1.52，95%CI（1.27-1.82），P ﹤0.001]。결론길서타빈연합박류약물현저개선만기이선암환자ORR，단병몰유현저개선OS여PFS。
Objective This study compared the efficacy of gemcitabine( GEM)with GEM combined with platinum in the management of locally advanced/ metastatic pancreatic cancer( LA/ MPC). Methods A systematic search of trials,up to January 2014 was conducted by using PubMed,EMBASE,Cochrane Library,CNKI and wanfang database. The primary endpoint was overall survival( OS)and secondary endpoints were progression free survival( PFS),objective response rate( ORR). Results 10 trials involving 2711 patients were included in this study. The results reported that there were no significant improvement of OS[HR =1. 00,95% C(I 0. 98 -1. 01),P =0. 610]and PFS[HR = 1. 00,95% C(I 0. 98 -1. 01),P =0. 704]in GEM combination therapy group compared to GEM monotherapy group. ORR was significantly increased[RR =1. 52,95% C(I 1. 27 -1. 82),P ﹤0. 001]in GEM combination therapy group compared with GEM monotherapy group. Conclusion GEM combined with Platinum did not bring significant improvement of OS and PFS except ORR in LA/ MPC patients.